ES2188426B1 - Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. - Google Patents
Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.Info
- Publication number
- ES2188426B1 ES2188426B1 ES200102836A ES200102836A ES2188426B1 ES 2188426 B1 ES2188426 B1 ES 2188426B1 ES 200102836 A ES200102836 A ES 200102836A ES 200102836 A ES200102836 A ES 200102836A ES 2188426 B1 ES2188426 B1 ES 2188426B1
- Authority
- ES
- Spain
- Prior art keywords
- psoriasis
- treatment
- pharmaceutical composition
- composition
- dermopatias
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000011282 treatment Methods 0.000 title abstract 4
- 201000004681 Psoriasis Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 239000002904 solvent Substances 0.000 abstract 3
- BFZHCUBIASXHPK-QJSKAATBSA-N 11alpha-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)C[C@H]2O BFZHCUBIASXHPK-QJSKAATBSA-N 0.000 abstract 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 abstract 2
- 229960004703 clobetasol propionate Drugs 0.000 abstract 2
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 abstract 2
- 235000011187 glycerol Nutrition 0.000 abstract 2
- 239000006210 lotion Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- IWRPVTXREVYBHT-ZQEATNLPSA-N [(8s,9s,10r,11r,13s,14s,17s)-17-acetyl-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-11-yl] acetate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@H](OC(=O)C)C[C@]4(C)[C@@H](C(C)=O)CC[C@H]4[C@@H]3CCC2=C1 IWRPVTXREVYBHT-ZQEATNLPSA-N 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 229960001334 corticosteroids Drugs 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- 239000012049 topical pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composición farmacéutica para el tratamiento de la psoriasis y otras dermopatías. Comprende 17-propionato de clobetasol, 11alfa- hidroxiprogesterona (o alternativamente 11 alfa- acetoxiprogesterona) y cantidades adecuadas de excipientes para constituir una formulación tópica. Preferiblemente se administra como loción con: 0,05-0,2% de 17-propionato de clobetasol; 0,3-1% de 11alfa-hidroxiprogesterona; un disolvente seleccionado entre etanol, isopropanol y sus mezclas; un 40% de codisolvente seleccionado entre propilenglicol, glicerina, sorbitol y sus mezclas; y un 20% de agua. Es especialmente preferida la loción donde el disolvente es etanol, y los codisolventes son aproximadamente: 35% de propilenglicol, 5% de glicerina y 20% de agua. Respecto a los tratamientos conocidos con corticoides tópicos, la composición de la invención presenta las ventajas de una recidiva mucho más espaciada y de muchos menos efectos secundarios locales. La composición es útil para el tratamiento de la psoriasis.
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200102836A ES2188426B1 (es) | 2001-12-12 | 2001-12-12 | Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. |
PCT/ES2002/000591 WO2003053991A1 (es) | 2001-12-12 | 2002-12-11 | Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias |
PT02796785T PT1473300E (pt) | 2001-12-12 | 2002-12-11 | Composição farmacêutica para o tratamento de psoríase e outras doenças de pele |
AU2002361265A AU2002361265A1 (en) | 2001-12-12 | 2002-12-11 | Pharmaceutical composition for the treatment of psoriasis and other skin diseases |
EP02796785A EP1473300B1 (en) | 2001-12-12 | 2002-12-11 | Pharmaceutical composition for the treatment of psoriasis and other skin diseases |
CA002470364A CA2470364A1 (en) | 2001-12-12 | 2002-12-11 | Pharmaceutical composition for the treatment of psoriasis and other skin diseases |
ES02796785T ES2318061T3 (es) | 2001-12-12 | 2002-12-11 | Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. |
AT02796785T ATE415410T1 (de) | 2001-12-12 | 2002-12-11 | Pharmazeutische zusammensetzung zur behandlung von psoriasis und anderen hautkrankheiten |
DE60230066T DE60230066D1 (de) | 2001-12-12 | 2002-12-11 | Pharmazeutische zusammensetzung zur behandlung von psoriasis und anderen hautkrankheiten |
JP2003554707A JP2005513139A (ja) | 2001-12-12 | 2002-12-11 | 乾癬及び他の皮膚疾患の治療のための製薬組成物 |
US10/865,991 US20040225140A1 (en) | 2001-12-12 | 2004-06-11 | Pharmaceutical composition for the treatment of psoriasis and other skin diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200102836A ES2188426B1 (es) | 2001-12-12 | 2001-12-12 | Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2188426A1 ES2188426A1 (es) | 2003-06-16 |
ES2188426B1 true ES2188426B1 (es) | 2004-11-16 |
Family
ID=8499799
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES200102836A Expired - Lifetime ES2188426B1 (es) | 2001-12-12 | 2001-12-12 | Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. |
ES02796785T Expired - Lifetime ES2318061T3 (es) | 2001-12-12 | 2002-12-11 | Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES02796785T Expired - Lifetime ES2318061T3 (es) | 2001-12-12 | 2002-12-11 | Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20040225140A1 (es) |
EP (1) | EP1473300B1 (es) |
JP (1) | JP2005513139A (es) |
AT (1) | ATE415410T1 (es) |
AU (1) | AU2002361265A1 (es) |
CA (1) | CA2470364A1 (es) |
DE (1) | DE60230066D1 (es) |
ES (2) | ES2188426B1 (es) |
PT (1) | PT1473300E (es) |
WO (1) | WO2003053991A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2898498B1 (fr) * | 2006-03-15 | 2008-11-28 | Galderma Sa | Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant |
FR2898499B1 (fr) * | 2006-03-15 | 2008-11-28 | Galderma Sa | Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant |
ES2288133B1 (es) | 2006-06-12 | 2008-09-16 | Maria Cristina Fernandez Rodriguez | Composicion topica para el tratamiento de la psoriasis. |
DE602006009511D1 (de) * | 2006-08-17 | 2009-11-12 | Klever Mode S L | Pharmazeutische Zusammensetzungen zur Behandlung von Hauterkrankungen |
ES2489615T3 (es) | 2007-12-11 | 2014-09-02 | Apoteknos Para La Piel, S.L. | Uso de un compuesto derivado del acido p-hidroxifenil propionico para el tratamiento de la psoriasis |
EP2701744A4 (en) * | 2011-03-23 | 2014-08-20 | Pop Test Cortisol Llc | COMBINATION THERAPY |
PT2782584T (pt) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Preparações e terapias de substituição para hormonoterapias naturais combinadas |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10098894B2 (en) | 2014-07-29 | 2018-10-16 | Therapeuticsmd, Inc. | Transdermal cream |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US20180235882A1 (en) | 2015-09-02 | 2018-08-23 | Cadila Healthcare Limited | Topical compositions comprising corticosteroids |
KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3966924A (en) * | 1974-11-13 | 1976-06-29 | Allergan Pharmaceuticals | Composition and method for treating psoriasis |
JPS56135416A (en) * | 1980-03-27 | 1981-10-22 | Mitsubishi Chem Ind Ltd | Pharmaceutical preparation for skin |
KR100282575B1 (ko) * | 1992-02-07 | 2001-02-15 | 알버트엠.클릭만 | 염증성 피부병치료용 약제학적 조성물 |
WO1994013257A1 (en) * | 1992-12-16 | 1994-06-23 | Creative Products Resource Associates, Ltd. | Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder |
CA2282682C (en) * | 1997-02-20 | 2008-08-19 | Allergan Sales, Inc. | Tazarotene and corticosteroid treatment for psoriasis |
US5972920A (en) * | 1998-02-12 | 1999-10-26 | Dermalogix Partners, Inc. | Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders |
-
2001
- 2001-12-12 ES ES200102836A patent/ES2188426B1/es not_active Expired - Lifetime
-
2002
- 2002-12-11 DE DE60230066T patent/DE60230066D1/de not_active Expired - Lifetime
- 2002-12-11 EP EP02796785A patent/EP1473300B1/en not_active Expired - Lifetime
- 2002-12-11 CA CA002470364A patent/CA2470364A1/en not_active Abandoned
- 2002-12-11 AU AU2002361265A patent/AU2002361265A1/en not_active Abandoned
- 2002-12-11 AT AT02796785T patent/ATE415410T1/de active
- 2002-12-11 ES ES02796785T patent/ES2318061T3/es not_active Expired - Lifetime
- 2002-12-11 WO PCT/ES2002/000591 patent/WO2003053991A1/es active Application Filing
- 2002-12-11 PT PT02796785T patent/PT1473300E/pt unknown
- 2002-12-11 JP JP2003554707A patent/JP2005513139A/ja active Pending
-
2004
- 2004-06-11 US US10/865,991 patent/US20040225140A1/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
BARAN, R. et al.: "Topical treatment of nail psoriasis with a new corticoid-containing nail lacquer formulation". J. of Dermatological Treatment, 1999, Volumen 10, páginas 201-204, todo el documento. * |
SWINKELS, O.Q.J. et al.: "The influence of a topical corticosteroid on short-contact high-dose dithranol therapy". British J. of Dermatology, 2001, Volumen 145, páginas 63-69, todo el documento. * |
Also Published As
Publication number | Publication date |
---|---|
EP1473300A1 (en) | 2004-11-03 |
ATE415410T1 (de) | 2008-12-15 |
PT1473300E (pt) | 2009-02-27 |
JP2005513139A (ja) | 2005-05-12 |
ES2188426A1 (es) | 2003-06-16 |
EP1473300B1 (en) | 2008-11-26 |
WO2003053991A1 (es) | 2003-07-03 |
AU2002361265A1 (en) | 2003-07-09 |
US20040225140A1 (en) | 2004-11-11 |
ES2318061T3 (es) | 2009-05-01 |
DE60230066D1 (de) | 2009-01-08 |
CA2470364A1 (en) | 2003-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2188426B1 (es) | Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. | |
AR028833A1 (es) | Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion | |
AR026593A1 (es) | Formulaciones para agentes farmaceuticos ionizables como acidos libres o bases libres | |
ECSP941104A (es) | Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
ES2186015T3 (es) | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol. | |
AR003220A1 (es) | Derivados acilados de melatonina; composicion farmaceutica y cosmetica y el uso de los mismos para la preparacion de un medicamento. | |
UY28510A1 (es) | Compuestos quimicos | |
DE60027463D1 (de) | Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon | |
UY26977A1 (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgésicos | |
HN2004000232A (es) | " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden." | |
ECSP066972A (es) | Profármacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y métodos | |
CR7716A (es) | Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor | |
AR029634A1 (es) | Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento | |
SV1999000009A (es) | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol ref. pg3388/sv | |
ATE249214T1 (de) | Pentafluorobenzensulfonamide und analoge | |
MX9301348A (es) | Nuevos compuestos que tienen actividad farmacologica, proceso para su preparacion y composicion farmaceutica que los comprende. | |
UY28979A1 (es) | Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3 | |
PE20020348A1 (es) | Exemestano como agente quimiopreventivo | |
ES2102994T3 (es) | Derivados de benzisotiazolinona-1-dioxido como inhibidores de elastasa. | |
EA200100226A1 (ru) | Топикальные, содержащие нимесулид фармацевтические составы | |
CL2003002565A1 (es) | Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci | |
PA8534001A1 (es) | Derivados de piperazina 1,4-disustituida utiles como bloqueadores alfa1,-adrenoceptores uro-selectivos | |
AR018162A1 (es) | Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica | |
ES2188995T3 (es) | Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales. | |
PA8525801A1 (es) | Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EC2A | Search report published |
Date of ref document: 20030616 Kind code of ref document: A1 |
|
FG2A | Definitive protection |
Ref document number: 2188426B1 Country of ref document: ES |
|
FA2A | Application withdrawn |
Effective date: 20050401 |